The five deals that mattered most on 9 November 2026 across biotech, medtech and pharma, and what each one means. A quiet weekend for AI and energy: no deal in those areas met our threshold. Every item links to its original source.
Biotech M&A · US · 9 Nov
argenx buys Unnatural Products for $550M upfront and up to $1.15B to own its oral peptide platform
argenx acquires all of Unnatural Products (UNP) for $550M in cash plus contingent value rights tied to development and regulatory milestones, for a total of up to about $1.15B. Closing is expected by the end of the year. UNP, founded in 2016 by two UC Santa Cruz PhD students in a garage, now employs more than 50 people and designs orally delivered macrocyclic peptides for targets that are hard to drug, combining AI guided design, massively parallel synthesis and direct to biology screening. Novartis, Merck and BridgeBio partnered with UNP before argenx, which has worked with the company for more than two years and already held a minority stake. Santa Cruz becomes argenx’s peptide discovery hub, with the UNP team staying in place.
Why it matters: A European immunology leader buys a discovery engine rather than a single drug, and ties more than half of the price to milestones.
Source: Unnatural Products press release
MedTech IPO · Switzerland · 6 Nov
vVardis sets terms for a $214M New York listing of its drill free cavity treatment
The Zug company offers 9.52M shares at $21 to $24 each, about $214M at the midpoint, and plans to list on the New York Stock Exchange under the ticker VVVV. Goldman Sachs and J.P. Morgan lead the offering, with William Blair, UBS and Deutsche Bank as bookrunners. vVardis sells Curodont, a peptide based treatment for early cavities that works without drilling or needles; its lead product is sold over the counter in the United States. The terms are in the amended registration filed on 6 November, with pricing expected this week.
Why it matters: A Swiss dental company chooses New York over Zurich for its listing, betting on the US market where its product already sells.
Source: vVardis F-1/A, SEC
Biotech financing · Germany · 9 Nov
SRTD Biotech raises a €31.5M seed round for RNA drugs that switch on only in diseased cells
Mérieux Equity Partners, NRW.BANK and the Boehringer Ingelheim Venture Fund co-led the oversubscribed round, joined by Lilly Ventures, HTGF and Anobis Asset. SRTD designs selectively expressed RNA that stays inactive until it meets a specific disease marker inside a cell, delivered with fusogenic lipid nanoparticles and designed on an AI driven platform. The money funds four preclinical programmes in primary liver and lung cancer, liver fibrosis and autoimmune disease. The technology goes back to research at Forschungszentrum Jülich.
Why it matters: Two big pharma venture arms in a German seed round sized like a Series A show how early strategic money now arrives in European biotech.
Source: Tech Funding News
Biotech licensing · Japan · 9 Nov
Edesa licenses Japan rights to its ARDS antibody paridiprubart to Kyorin for $12M upfront
Kyorin Pharmaceutical gains exclusive rights in Japan to paridiprubart, Edesa’s anti TLR4 antibody for acute respiratory distress syndrome, and funds development, regulatory work and launch there. Edesa receives $12M upfront, is eligible for up to about $134M in development, regulatory and sales milestones, and earns tiered double digit royalties on Japanese sales. Edesa keeps all rights outside Japan and will manufacture and supply the drug. Kyorin also has a first right to negotiate for acute kidney injury.
Why it matters: A small company funds its lead programme with a regional partner instead of new shares, and keeps the rest of the world for itself.
Source: Edesa Biotech press release, SEC
Pharma M&A · UK · 6 Nov
Dipharma buys LogixX Pharma, its UK partner for rare disease medicines for nearly ten years
Dipharma has completed the acquisition of LogixX Pharma, based in Theale, Berkshire; terms were not disclosed. LogixX, founded in 2010, supplies treatments for rare and metabolic conditions to the NHS and homecare providers, and has distributed Dipharma’s nitisinone and, since 2023, sapropterin in the UK. LogixX keeps its name, its CEO Michael Close and its team as a wholly owned subsidiary; its fertility business, now a separate company, was not part of the deal.
Why it matters: A long distribution partnership turns into ownership, giving Dipharma its own commercial base in the UK for future launches.
Source: Manufacturing Chemist
Every earlier day is in the Deals archive.
More news, conversations and analysis on The Briefing.
For information only. Not investment advice.